Immunic investor relations

Author: npsj

August undefined, 2024

Witryna23 lut 2024 · Immunic, Inc. (NASDAQ:NASDAQ:IMUX) Q4 2024 Earnings Conference Call February 23, 2024 8:00 AM ETCompany ParticipantsJessica Breu - Head, IR & CommunicationsDaniel Vitt - CEO, President... Witryna17 lis 2024 · Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. US IR Contact Rx Communications Group Melody Carey +1 917 322 2571 [email protected]. US Media Contact KOGS Communication Edna Kaplan +1 781 639 1910 [email protected]

Immunic gets a "positive surprise" from lead asset trial

http://www.neurobopharma.com/ Witryna5 kwi 2024 · Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune … Investor Relations. IR Home; News Releases; Events and Presentations; Stock … Webcasts and presentations that have been archived are available by viewing hi… 1200 Avenue of the Americas Suite 200 New York, NY 10036, USA Phone: +1 3… Immunic Therapeutics Jessica Breu Head of Investor Relations and Communic… Immunic is privately held and supported by several renowned healthcare invest… fma new legislation

Immunic, Inc. to Participate in Investor Conferences in September …

Witryna10 lis 2024 · Members of Immunic's management and investor relations teams will attend this virtual conference. To schedule a meeting, please contact an Evercore representative. ... Head of Investor Relations ... Witryna4 paź 2024 · Members of Immunic's business development and investor relations teams will attend this conference in Leipzig, ... Head of Investor Relations and Communications +49 89 2080 477 09 Witryna13 kwi 2024 · Overview. Rocket Companies (NYSE: RKT) is a Detroit-based holding company consisting of personal finance and consumer service brands. Founded by Dan Gilbert, tech-driven Rocket Companies provides industry-leading real estate, mortgage and financial services, empowering consumers through entities including Rocket … fm and m

Immunic, Inc. Announces $60.0 Million Oversubscribed Private …

Witryna28 lip 2024 · Q1 2024 Athenex Inc. Earnings Conference Call. Monday, March 01, 2024 8:00 am EST. Q4 and Full Year 2024 Athenex, Inc. Earnings Conference Call. Monday, January 11, 2024 8:40 am EST. ATNX at 39th Annual J.P. Morgan Healthcare Conference. Wednesday, December 09, 2024 5:00 pm EST. Witryna5 kwi 2024 · Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. US IR Contact Rx Communications Group Paula Schwartz +1 917 633 7790 [email protected]. US Media Contact KOGS Communication Edna Kaplan +1 617 974 8659 [email protected] fma newcastleWitryna29 kwi 2016 · About Immunic. Immunic AG (www.immunic.de) is a start-up biotech company founded in April 2016 and focused on the development of immune modulators to block Th17- and Th1-mediated immune and autoimmune responses. The company’s two development programs include orally available, small molecule inhibitors of … f mangle3 29° what is mangle4

"Witryna14 lip 2024 · NEW YORK, July 14, 2024 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX ), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies ... " - Immunic investor relations

Immunic investor relations

Witryna6 lis 2024 · Immunic, Inc. (NASDAQ:NASDAQ:IMUX) Q3 2024 Earnings Conference Call November 3, 2024 8:00 AM ETCompany ParticipantsJessica Breu - Head, IR and … Witryna10 paź 2024 · Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected] US IR Contact Rx …

Did you know?

Witryna10 paź 2024 · Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release. Contact Information Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. Rx Communications Group Paula Schwartz +1 … Witryna1 wrz 2024 · Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Head of Investor Relations and Communications at Immunic, will …

Witryna12 kwi 2024 · For Institutional Investors, Securities Analysts. Phone line：+81-3-3244-3022. Business hours (JST): From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm (closed on Saturdays, Sundays, national holidays and company holidays) Witryna25 kwi 2024 · Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. US IR Contact Rx …

Witryna3 lis 2024 · Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release. Contact Information. Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. US IR Contact Rx Communications Group … Witryna3 lis 2024 · Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected] US IR Contact Rx …

WitrynaManager Investor Relations and Communications Immunic AG. 2 Jahre und 6 Monate, Mai 2016 - Okt. 2024. Junior Consultant Public and Investor Relations MC Services AG. 1 Jahr und 2 Monate, März …

Witryna26 lut 2024 · Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release. Contact Information. Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. US IR Contact Rx Communications Group … greensboro islamic center ictWitryna3 mar 2024 · We disclaim any obligation to supplement or update the information in these press releases. Year. 2024. March 27, 2024. Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs) March 23, 2024. Incyte Provides Regulatory Update on Ruxolitinib … greensboro islamic academyWitryna13 kwi 2024 · Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC). Vitt describes it as "wonderful data" that came as a "positive … fm and g mirrorsWitrynaAll Events Quarterly Earnings Healthcare Conferences Other Investor Events. 03.07.2024. Cowen 43rd Annual Health Care Conference. Presentation. Transcript. Webcast. 02.16.2024. SVB Securities Global Biopharma Conference. Transcript. fma night visionWitryna25 kwi 2024 · NEW YORK, April 25, 2024 /PRNewswire/ -- Immunic, Inc. , a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic... April 10, 2024 f ma newton\\u0027s 2nd lawWitryna3 lis 2024 · Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release. Contact Information. … f ma newton lawWitryna14 kwi 2024 · Immunic Inc. (NASDAQ: IMUX)’s stock price has soared by 10.14 in relation to previous closing price of 1.38. Nevertheless, the company has seen a loss of -1.94% in its stock price over the last five trading days. According a new report published by BloombergNEF on investment in the energy ... fm anlage phonak